WO2016174861A1

WO2016174861A1 - Oral care composition

Info

Publication number: WO2016174861A1
Application number: PCT/JP2016/002171
Authority: WO
Inventors: 太郎川瀬; 竜二川瀬; 明美川瀬
Original assignee: ジャパンモード株式会社
Priority date: 2015-04-27
Filing date: 2016-04-25
Publication date: 2016-11-03
Also published as: MY186889A

Abstract

Provided is an oral care composition capable of completely preventing cavities by inducing the secretion of saliva in large quantities and thereby maintaining and improving the health of the oral cavity. Specifically provided is an oral care composition that is placed in the oral cavity to improve the health of the oral cavity, said oral care composition being characterized by comprising, in terms of mass% relative to the total mass of the composition, 1-30% phosphoryl organosaccharides of calcium, 0.01-10% lactoferrin, and 1-5% magnesium carbonate or 1-5% suicralose.

Description

Oral care composition

The present invention relates to an oral care composition, tablet, and granular drug suitable for maintaining oral health by secreting more saliva exhibiting antibacterial and antibacterial effects into the oral cavity.

Saliva has the action of keeping the oral cavity moist, smooth digestion of food, and cleaning the oral cavity by a physical or biochemical mechanism. Furthermore, this saliva maintains a constant pH in the oral cavity, and caries by maintaining the pH in the oral cavity to be more neutral by the action of bicarbonate ions (HCO ₃ ⁻ ) in the saliva ( It plays a role in preventing tooth decay. In other words, saliva plays an important role in eating and maintaining oral health.

However, in recent years, the population of so-called dry mice (xerostomia) in which oral tissues become dry due to a decrease in saliva secretion is increasing. When this dry mouse develops, it is accompanied by symptoms such as difficulty in swallowing food, and a decrease in antibacterial action due to a decrease in the amount of saliva. As a result, bacteria with nutrients from food residues grow and the oral environment deteriorates, causing oral diseases such as dental caries and periodontal disease and the development of bad breath. It can also lead to discomfort, trouble with swallowing and conversation.

By the way, not only the effects of salivary gland diseases and systemic diseases, but also various causes such as aging and side effects of medication are considered to cause dry mice to develop as saliva decreases. For this reason, it is often difficult to completely eliminate these causes when treating dry mice.

Under such circumstances, conventional treatments for dry mice include salivary gland consisting of acids, plant extracts, etc., as well as methods of physically stimulating salivary glands by salivary gland massage and chewing to directly promote salivary secretion. A method of promoting secretion of saliva by causing a secretagogue or a food containing them to act in the oral cavity has been proposed (see, for example, Patent Document 1). In addition, as a method for moisturizing the oral cavity, a method has been proposed in which a composition containing a moisturizing component containing a high molecular weight component is included in the oral cavity.

JP-A-11-71253 JP 2007-84501 A

However, according to the above-described conventional technology, although saliva secretion can be promoted and dry mouth symptoms can be improved, there is a problem in that the amount of saliva secretion cannot be dramatically increased. In addition, the above-described conventional technology is suitable for use in combination with eye drops or nasal drops, for example, or when a tablet with a saliva secretion component is coated around the tablet to make it easier for people with dry mouth symptoms to take tablets. Not configured. In addition, the above-described conventional technology is not suitable for a case where it is manufactured and sold by mixing with granules or a powdered medicine, or when it is used by mixing with cosmetics, champignons, sprays, gels and the like. Furthermore, the above-described conventional technology is not suitable for a combination with food or beverage.

In other words, it dramatically improves the dry mouth symptom by dramatically increasing the amount of saliva secretion, and the composition suitable for applying the same composition to various other uses as well as the improvement of the dry mouse. Has long been desired.

Therefore, the present invention has been devised in view of the above-mentioned problems, and the purpose thereof is to further improve dry mouth symptoms by dramatically increasing the amount of saliva secretion, An object of the present invention is to provide an oral care composition, tablet, and granular drug suitable for developing the same composition to other uses.

The oral care composition according to the first aspect of the present invention is an oral care composition that promotes health in the oral cavity by being contained in the oral cavity, and is phosphorylated oligosaccharide calcium: 1% to 30% by mass relative to the total mass of the composition. %, Lactoferrin: 0.01% to 10%.

The oral care composition according to the second invention is characterized in that, in the first invention, it further contains sodium bicarbonate: 1% to 20%.

The oral care composition according to the third invention is characterized in that in the first invention or the second invention, it further contains potassium carbonate or potassium hydrogen carbonate: 1% to 5%.

The oral care composition according to the fourth invention is characterized in that, in the first invention, it further contains magnesium carbonate: 1 to 5%.

The oral care composition according to the fifth invention is characterized in that in the first invention, it further contains sucralose: 1 to 5%.

The ophthalmic solution according to the sixth aspect of the invention contains an eye drop component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0 .01% to 10%.

The nasal solution according to the seventh invention contains a nasal drug component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin : It is characterized by containing 0.01 to 10%.

The cosmetic according to the eighth invention contains a cosmetic ingredient and an auxiliary ingredient, and the auxiliary ingredient is in mass% based on the total mass of the auxiliary ingredient, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0 .01% to 10%.

The cleansing composition for skin or hair according to the ninth aspect of the invention contains a cleaning component and an auxiliary component, and the auxiliary component is a mass% based on the total mass of the auxiliary component, and phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.01 to 10%.

The hair treatment composition according to the tenth aspect of the invention contains a hair treatment component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: It is characterized by containing 0.01 to 10%.

The food composition according to the eleventh aspect of the present invention contains an edible component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0 .01% to 10%.

The beverage composition according to the twelfth aspect of the present invention comprises a beverage component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: It is characterized by containing 0.01 to 10%.

The seasoning composition according to the thirteenth aspect of the invention contains a seasoning component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin : It is characterized by containing 0.01 to 10%.

According to a fourteenth aspect of the present invention, there is provided a method for producing a pharmaceutical product comprising: a transporting step in which the nucleating agent containing the drug component is transported in the manufacturing method of the pharmaceutical component containing the pharmaceutical component; and the nucleating agent transported in the transporting step. In the above addition step, phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% are added in mass% with respect to the total mass of the auxiliary components. It is characterized by that.

According to a fifteenth aspect of the present invention, there is provided a method for designing a pharmaceutical product comprising: an information acquisition step for acquiring information related to a patient in a method for designing a pharmaceutical product containing a drug component; A design step of designing the content of phosphorylated oligosaccharide calcium and lactoferrin contained in the components. In the design step, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin in mass% with respect to the total mass of the auxiliary components : Designed to be included in 0.01 to 10%.

The chemical composition production method according to the sixteenth aspect of the invention is a chemical composition production method comprising a main component that exhibits a predetermined effect. In the conveyance step, the main agent containing the main component is conveyed; An addition step of adding an auxiliary component to the main agent that has been conveyed. In the addition step, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.0. It is characterized by adding 01 to 10%.

The chemical composition design method according to the seventeenth aspect of the invention is a chemical composition design method containing a main component that exhibits a predetermined effect. In the information acquisition step of acquiring information about a subject, and in the information acquisition step, Based on the acquired information, a design process for designing the content of phosphorylated oligosaccharide calcium and lactoferrin contained in the auxiliary component to be added. It is characterized by being designed to be contained in calcium oxide oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10%.

The method for producing a food / beverage composition according to the eighteenth aspect of the invention is a method for producing a food / beverage composition containing a food / beverage component, wherein the food / beverage material containing the food / beverage ingredient is conveyed, and conveyed in the conveyance step. And an addition step of adding an auxiliary component to the above-mentioned food and drink. In the addition step, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.0. It is characterized by adding 01 to 10%.

The food / beverage composition design method according to the nineteenth aspect of the invention is a food / beverage composition design method containing a food / beverage component, in the information acquisition step of acquiring information about a food / beverage and the information acquired in the information acquisition step. Based on the design step of designing the content of phosphorylated oligosaccharide calcium and lactoferrin contained in the auxiliary component to be added, and in the above design step, phosphorylated oligosaccharide calcium in mass% with respect to the total mass of the auxiliary component 1 to 30% and lactoferrin: 0.01 to 10%.

The treatment method according to the twentieth aspect of the present invention is a supplement comprising a main component exhibiting a predetermined effect and phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% relative to the total mass of the auxiliary component. It is characterized in that a chemical composition containing components is applied to a subject.

The treatment method according to the twenty-first aspect of the present invention is to provide an oral wearing body in which an auxiliary component containing phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% in mass% with respect to the total mass of the auxiliary component is loaded. It is characterized in that it is mounted in the oral cavity of the subject and the auxiliary components inserted in the oral cavity dressing are gradually dissolved in the oral cavity of the subject.

The oral wearing body according to the twenty-second invention is loaded with auxiliary components containing phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% with respect to the total mass of the auxiliary components. The auxiliary component is gradually dissolved in the oral cavity of the subject by being mounted in the oral cavity.

The tooth pain relieving agent according to the twenty-third aspect of the present invention contains an auxiliary component, and the auxiliary component is in mass% based on the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10% And lactoperoxidase: 1 to 20%.

The hypothermia-improving agent according to the twenty-fourth aspect of the present invention contains an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10 %, Magnesium sulfate: 1 to 70%.

The hypothermia improving agent according to the twenty-fifth aspect of the present invention contains an auxiliary component, and the auxiliary component is mass% relative to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10 %, Total of vitamin B group: 1 to 10%.

The hypothermia-improving agent according to the twenty-sixth aspect of the present invention contains an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10 %, Blood circulation promoter: 10 to 30%.

According to the present invention having the above-described configuration, by including it in the oral cavity of a subject, the phosphorylated oligosaccharide calcium and lactoferrin contained in this oral care composition act synergistically due to the presence of each other, A large amount of saliva will be secreted. At this time, secretion of saliva will be further promoted by containing the above-mentioned sodium bicarbonate, potassium carbonate, or potassium bicarbonate.

In this way, the secretion of saliva in the oral cavity is dramatically promoted, so that the digestion of food is helped and the self-cleaning action of washing away the food residue in the oral cavity is enhanced. In addition, the bactericidal action in the oral cavity is also exhibited, and furthermore, the pH in the oral cavity is maintained so as to be more alkaline, it is possible to prevent the occurrence and progression of caries, and the action of remineralization Can also be exhibited. In addition, the oral care composition to which the present invention is applied can alleviate the symptoms of dry mice that frequently appear in the elderly and the like by promoting the secretion of saliva in the oral cavity.

In addition, the present invention has a configuration suitable for use in combination with, for example, eye drops or nasal drops, or when it is easy to drink tablets even for people with dry mouth symptoms by coating the secretion component of saliva around the tablets. can do. In addition, the present invention can be configured to be suitable for the case where it is manufactured and sold by mixing it with granules or powdered drugs, or when it is used by mixing with cosmetics, champlins, sprays, gels and the like. Moreover, this invention can be set as the structure suitable in the case of combining with a food and a drink.

That is, according to the present invention having the above-described configuration, the dry mouth symptom is dramatically improved by dramatically increasing the amount of saliva secreted, and the same composition can be used to improve not only the dry mouse but also other It becomes possible to set it as the structure suitable when applying to various uses.

In particular, in the present invention, it is possible to promote the secretion of a large amount of saliva, so even in places where there is no water such as disaster areas, by including this in the mouth, the occurrence of caries without brushing teeth and Progression can be prevented. In addition, people who have difficulty brushing their teeth, such as the elderly and the physically handicapped, can prevent the occurrence and progression of dental caries without brushing their teeth by including the oral care composition to which the present invention is applied in the mouth. It becomes possible.

It is a figure for demonstrating the example in the case of applying this invention to a tablet. It is a figure for demonstrating the whole flow about the manufacturing method of the pharmaceutical to which this invention is applied. It is a figure for demonstrating the whole flow which introduced the design process about the manufacturing method of the pharmaceutical to which this invention is applied. It is a figure for demonstrating the whole flow about the manufacturing method of the chemical composition to which this invention is applied. It is a figure for demonstrating the whole flow which introduced the design process about the manufacturing method of the chemical composition to which this invention is applied. It is a figure which shows the structure of the oral cavity mounting body used for an actual treatment.

In order to solve the above-mentioned problems, the present inventors have focused on the action expressed by saliva and invented an oral care composition capable of secreting a large amount of this to promote health maintenance in the oral cavity. did. The main effects expressed by saliva are as follows.

Saliva contains the digestive enzyme amylase. This amylase develops an effect of facilitating absorption in the body by decomposing carbohydrates contained in food. Saliva has an effect of helping food digestion by including such an amylase as an enzyme.

Moreover, a food bolus of an appropriate size can be generated by mixing the food in the oral cavity with saliva. For this reason, saliva has an effect of helping to swallow food. Saliva also exerts a so-called self-cleaning action to wash away the meal in the oral cavity. That is, the amount of saliva secreted by chewing well increases and the self-cleaning action is enhanced.

Saliva also contains lysozyme that exerts antibacterial action against bacteria entering from the outside through the mouth and nose. Moreover, the saliva also serves to wash out the inside of the oral cavity, and a large amount of saliva is secreted, so that dirt in the oral cavity can be removed and thus bad breath can be prevented.

Saliva also plays a role of keeping the pH in the oral cavity constant, so-called buffering action. By the action of bicarbonate ions (HCO ₃ ⁻ ) in saliva, the pH in the oral cavity is maintained to be more neutral. In general, caries (decayed tooth) starts with so-called demineralization, where the pH in the oral cavity tends to become acidic due to the generation of a large amount of acid in the plaque and the calcium and minerals on the tooth surface begin to dissolve. Become. However, since a large amount of saliva is secreted, the oral cavity quickly returns to neutrality based on the buffering action of saliva itself.

Furthermore, saliva exhibits a so-called remineralization action that replenishes and repairs calcium and minerals on tooth surfaces that have been dissolved by acid.

The present inventors diligently examined conditions for more appropriately exerting the action of these saliva. As a result, it was experimentally verified that saliva can be secreted in a larger amount by including an oral care composition comprising the following components and including it in the oral cavity of the subject. As a result, the inventors have newly found that saliva secretion can be dramatically increased based on the synergistic effect of mixing phosphorylated oligosaccharide calcium and lactoferrin. This phosphorylated oligosaccharide calcium is a substance that is hardly soluble in water, whereas lactoferrin is a substance that is easily soluble in water. That is, it is based on an unprecedented idea of mixing phosphorylated oligosaccharide calcium and lactoferrin having different hydration properties into one oral care composition.

That is, the oral care composition according to the present invention is an oral care composition that promotes health in the oral cavity by being contained in the oral cavity, and is phosphorylated oligosaccharide calcium: 1% by mass relative to the total mass of the composition: Contains 30%, lactoferrin: 0.01-10%. The oral care composition may further contain magnesium carbonate: 1 to 5%. Further, the oral care composition may contain sucralose: 1 to 5%. Further, the oral care composition to which the present invention is applied may contain sodium bicarbonate: 1 to 20%, or contain 1 to 5% potassium carbonate or potassium bicarbonate. Good.

In the oral care composition to which the present invention is applied, the remainder may contain any one or more of indigestible dextrin, jumpinion extract powder, xylitol, fragrance, fine silicon dioxide, calcium stearate and the like.

Hereinafter, the reasons for limiting the components and content of the oral care composition to which the present invention is applied will be described. In addition, the content of each component is expressed by mass% with respect to the total mass of the composition, and when expressing the mass%, it is simply expressed as%.

Phosphorylated oligosaccharide calcium: 1-30%
Phosphorylated oligosaccharide calcium is a starch-derived component derived from Hokkaido potatoes. Potato starch has a portion to which a phosphate group is bonded, and the starch is extracted and purified by allowing an enzyme to act on the starch to prepare a calcium salt, which is phosphorylated oligosaccharide calcium. This phosphorylated oligosaccharide calcium causes the action of secreting a large amount of saliva by being contained in the oral cavity. In addition to exerting the function as a calcium source, this phosphorylated oligosaccharide calcium does not become a nutrient source for mutans streptococcus, a cariogenic bacterium, and further reduces the pH in the oral cavity by a buffering action. The function to suppress can be demonstrated. Phosphorylated oligosaccharide calcium can promote tooth remineralization by enhancing dissolved calcium ions in saliva.

When the content of phosphorylated oligosaccharide calcium is less than 1%, the functions originally possessed by phosphorylated oligosaccharide calcium cannot be exhibited, and the above-mentioned desired effects cannot be achieved. On the other hand, when the content of phosphorylated oligosaccharide calcium exceeds 30%, the effect is saturated, and the raw material cost is increased by containing a large amount thereof. If a large amount of phosphorylated oligosaccharide calcium is added to exceed 30%, it becomes extremely toxic to infants. Therefore, the content of phosphorylated oligosaccharide calcium is 1-30%.

Lactoferrin: 0.01-10%
Lactoferrin is an iron-binding glycoprotein having a molecular weight of about 80,000 that is widely distributed in the animal body. Lactoferrin is made from mammals (eg, humans, cows, goats, sheep, horses, etc.) colostrum, transitional milk, normal milk, end milk, or processed milk products of skim milk, whey, etc. For example, by using a known separation / purification method such as ion exchange chromatography, it is possible to use those obtained by separation from the raw materials. This lactoferrin may be produced from a plant (tomato, rice, tobacco) or may be obtained by genetic recombination. Furthermore, lactoferrin may be a commercially available product or can be prepared and used by a known method. Lactoferrin can be used alone or in combination of two or more. Such a lactoferrin causes an action of secreting a large amount of saliva by being included in the oral cavity.

The core functions that this lactoferrin can play include introduction of immune tolerance, enhancement of foreign body recognition, inhibition of angiogenesis, enhancement of opioid action, and the like. The introduction of immune tolerance can be expected to improve autoimmune diseases and various allergies. Further, by enhancing foreign object recognition, for example, an improvement effect can be expected for infectious diseases, particularly opportunistic infections. In addition, lactoferrin has an effect of inhibiting angiogenesis induced by inflammation, and is therefore effective for angiogenic diseases such as cancer. On the other hand, lactoferrin enhances the effect of endogenous opioids called intracerebral narcotics, and thus can also exert an analgesic effect on pain.

Lactoferrin can also exert an effect on the repair of the conjunctival mucosa and the rejuvenation of the lacrimal gland in addition to the saliva secretion effect described above. Therefore, the effect of improving so-called dry eye can be expected by instilling such lactoferrin. Lactoferrin may also be able to treat and prevent neurodegenerative diseases such as Alzheimer's disease.

If the content of lactoferrin is less than 0.01%, the functions inherent to lactoferrin cannot be exhibited, and the above-described effects cannot be achieved. On the other hand, when the content of lactoferrin exceeds 10%, the effect is saturated, and the raw material cost is increased by containing a large amount thereof. In addition to this, when the content of lactoferrin exceeds 10%, the blood sugar level of the patient who has taken it increases. For this reason, the content of lactoferrin is set to 0.01 to 10%.

The present invention may contain the following components in addition to the phosphorylated oligosaccharide calcium and lactoferrin described above.

Sodium bicarbonate: 1-20%
Sodium bicarbonate (sodium bicarbonate) is commonly referred to as baking soda. As an additive such as calf powder and soft drinks, in various food fields, as well as in pharmaceutical fields such as artificial dialysates and gastrointestinal drugs, fire extinguishing agents, Widely used as bathing agent, cleaning agent, etc. Inclusion of such sodium bicarbonate in the oral cavity causes an action to secrete a large amount of saliva.

If the content of sodium bicarbonate is less than 1%, the functions inherently possessed by sodium bicarbonate cannot be achieved, and the above-mentioned desired effects cannot be achieved. On the other hand, when the content of sodium bicarbonate exceeds 20%, the effect is saturated. For this reason, the content of sodium bicarbonate is set to 1 to 20%.

Incidentally, the content of this sodium bicarbonate is preferably 6 to 16%, and more preferably 10 to 16%, in order to achieve the desired effect. As an example of this desirable sodium bicarbonate, the reason that the upper limit is 16% is that when sodium bicarbonate exceeding 16% is added, nausea may be felt, resulting in a composition that tends to vomit.

Potassium carbonate: 1-5%
Potassium carbonate has long been a general-purpose component in many fields such as pharmaceuticals, foods, and cosmetics, and is blended in pharmaceuticals as an antacid or acidosis inhibitor, or used as a component of an oral hydration agent. In addition, potassium carbonate can also function as a buffering agent that makes saliva alkaline or maintains an alkaline state. Inclusion of such potassium carbonate in the oral cavity causes an action to secrete a large amount of saliva.

If the content of potassium carbonate is less than 1%, the functions originally possessed by potassium carbonate cannot be exhibited, and the above-mentioned desired effects cannot be achieved. On the other hand, when the content of potassium carbonate exceeds 5%, the effect is saturated. Therefore, the content of potassium carbonate is 1 to 5%. In addition, you may make it add potassium hydrogencarbonate as an alternative of potassium carbonate.

In the present invention, the following components may be contained as necessary.

Phosphate source compound: 1-3%
The phosphoric acid source compound is a compound selected from the group consisting of phosphoric acid, sodium phosphate, potassium phosphate, polyphosphoric acid and cyclic phosphate. Among them, polyphosphoric acid is a compound formed by condensation of two or more phosphoric acids, and is frequently used as food excipients, discoloration inhibitors and the like. The degree of polymerization in polyphosphoric acid is arbitrary as long as it is 2 or more, for example, 2 or more and 10 or less. Examples of polyphosphoric acid include pyrophosphoric acid, triphosphoric acid, trimetaphosphoric acid, tetrametaphosphoric acid, and cyclopolyphosphoric acid. Examples of cyclic phosphoric acid include hexametaphosphoric acid. Polyphosphoric acid can suppress a decrease in intestinal barrier function and can exhibit a function of restoring the intestinal barrier function. Polyphosphate is synthesized from ATP by polyphosphate kinase in microorganisms such as E. coli. By including such polyphosphoric acid in the oral cavity, an action of secreting a large amount of saliva is caused. The phosphate source compound is desirably in the range of 1 to 3%.

Magnesium carbonate: 1-5%
Magnesium carbonate is mainly used as an abrasive or antacid for toothpaste. By mixing such magnesium carbonate, an effect of secreting a large amount of saliva is caused. When the content of magnesium carbonate is less than 1%, such saliva secretion effect cannot be achieved. On the other hand, if the content of magnesium carbonate exceeds 5%, the effect is saturated. Therefore, the content of magnesium carbonate is 1 to 5%.

Sucralose: 1-5%
Sucralose is one of the artificial sweeteners born from sucrose. Sucralose has about 600 times the sweetness of sucrose, is easily dissolved in water, and has excellent stability. In addition, sucralose has a mild sweetness similar to that of sugar, but it is not digested and absorbed as a carbohydrate in the body like sugar, and therefore has no physiological heat. For this reason, sucralose is applied to various beverage compositions and food compositions including soft drinks and ice creams. The sucralose exerts a mellow sweetness that produces a large amount of saliva. When the sucralose content is less than 1%, such saliva secretion effect cannot be achieved. On the other hand, when the content of sucralose exceeds 5%, the effect is saturated, and the raw material cost due to the inclusion of a large amount thereof increases. Therefore, the sucralose content is 1 to 5%.

The remainder of the indigestible dextrin is roasted dextrin obtained by acidification and / or heating of starch derived from plants such as corn, wheat, rice, beans, potatoes, tapioca, etc. And / or water-soluble dietary fiber that has been desalted and decolorized as necessary after treatment with glucoamylase, which has indigestible characteristics. In the oral care composition to which the present invention is applied, it is used as a bulking agent in the case of constituting as a tablet, and the content thereof is not particularly limited and is added in an appropriate amount.

Jumpinion extract powder is a component extracted from mushrooms and added in an appropriate amount to eliminate bad breath and other odors.

Xylitol is a naturally occurring pentose sugar alcohol, and what is added in the present invention may be any known source. By adding this xylito, it becomes possible to make it easy to drink when the oral care composition is constituted as a tablet. The content of xylitol is not particularly limited, and an appropriate amount is added.

The fragrance is obtained by blending many natural fragrances extracted from various plants and some animals, or synthetic fragrances synthesized chemically. For example, it becomes possible to make it easy to drink when the oral care composition is constituted as a tablet by adding an orange fragrance. In addition, by adding a menthol fragrance, it is possible to express a refreshing sensation when consumed. The content of the fragrance is not particularly limited, and an appropriate amount is added.

The fine silicon dioxide is a fine particle obtained by decomposing sodium silicate with hydrochloric acid or sulfuric acid, and is added in an appropriate amount to adjust the hardness, but the addition is not essential.

Calcium stearate is a calcium salt of stearic acid and palmitic acid, which uses palm-derived fatty acids that have the effect of increasing the lubricity, fluidity and preventing caking of powdered products, or emulsifying the product structure and increasing the viscosity. It is. The content of calcium stearate is not particularly limited, and an appropriate amount is added.

The oral care composition to which the present invention is applied may be embodied by solidifying each component having the above-described content as a tablet or powder, or may be embodied as a liquid. There may be.

By including such an oral care composition to which the present invention is applied in the oral cavity of a subject, the phosphorylated oligosaccharide calcium and lactoferrin contained in this oral care composition act synergistically due to the presence of each other. As a result, a larger amount of saliva is secreted. At this time, secretion of saliva will be further promoted by containing the above-mentioned sodium bicarbonate, potassium carbonate, or potassium bicarbonate. Since the calcium content of calcium phosphate oligosaccharide is quickly bound to lactoferrin and lactoferrin is less likely to be structurally destroyed by proteolytic enzymes, it can be structurally stabilized.

In this way, the secretion of saliva in the oral cavity is promoted, so that the digestion of food is helped and the self-cleaning action of washing away the food residue in the oral cavity is enhanced. In addition, bactericidal action in the oral cavity is also demonstrated, and furthermore, the pH in the oral cavity will be maintained to be more neutral, it becomes possible to prevent the occurrence and progression of caries, and remineralization It is also possible to exert the action.

Furthermore, the oral care composition to which the present invention is applied can alleviate the symptoms of dry mice that often appear in the elderly by promoting the secretion of saliva in the oral cavity.

In addition, when this invention is embodied as a pharmaceutical, what kind of chemical | medical agent may be applied as the chemical | medical agent component.

Supplied components are contained in an amount of 0.01 to 50% by mass based on the total mass of the pharmaceutical product. When the auxiliary component is less than 0.01% by mass% with respect to the total mass of the pharmaceutical product, the above-described effects as the auxiliary component cannot be exhibited. On the other hand, even if this auxiliary component is contained in an amount exceeding 50% by mass% with respect to the total mass of the pharmaceutical, the effect is saturated.

In addition, this invention is not limited to the case where it is comprised only by the oral care composition which consists of a compounding ratio of the component mentioned above. You may apply to the eye drop with which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. When it is embodied as an eye drop, it is embodied as an eye drop solution containing an auxiliary component composed of the blending ratio of the oral care composition described above and an eye drop component contained in a normal eye drop. As the eye drop component, for example, an anti-inflammatory agent, a vitamin agent, a vasoconstrictor, an antihistamine, a mydriatic agent, a miotic agent, an intraocular pressure-lowering agent, a cataract treatment agent, a steroid hormone agent, an antibiotic, a local anesthetic agent, hyperemia Examples include a removal component, an amino acid component, an antibacterial component, and the like, but are not limited thereto, and any other eye drop component may be mixed. The eye drop solution contains water and preservatives in addition to the eye drop component.

Supplied components are contained in an amount of 0.01 to 10% by mass with respect to the total mass of the eye drop solution. Incidentally, the phosphorylated oligosaccharide calcium and the lactoferrin in the auxiliary component may be configured to be instilled separately. In such a case, an ophthalmic solution consisting of phosphorylated oligosaccharide calcium and an ophthalmic component if necessary is placed in one container, and an ophthalmic solution consisting of lactoferrin and an ophthalmic component if necessary is placed in another container. . Then, instillation is performed with the eye drop solution in one of the containers, and after a while, instillation is performed with the eye drop solution in the other container. Thereby, the time of instillation of phosphorylated oligosaccharide calcium and lactoferrin can be shifted, and mixing of phosphorylated oligosaccharide calcium and lactoferrin in the eyes can be prevented.

According to the ophthalmic solution having the above-described configuration, so-called dry eye can be improved by the repairing action of the conjunctival mucosa and the rejuvenation action of lacrimal gland cells by lactoferrin. In addition, according to the present invention, the liquid oral care composition itself may be embodied as an eye drop solution.

Further, in the present invention, it may be applied to a nasal spray mixed with a component composed of the blending ratio of the oral care composition described above. When embodied as a nasal drop, it is embodied as a nasal drop containing an auxiliary component comprising the blending ratio of the oral care composition described above and a nasal drop component contained in a normal nasal drop. Examples of the nasal spray component include a vasoconstrictor, a vasodilator, an antihistamine, a steroid and the like, but are not limited thereto, and any other nasal spray component may be mixed.

Auxiliary components are contained in an amount of 0.01 to 10% by mass% based on the total mass of nasal drops. Incidentally, the phosphorylated oligosaccharide calcium and the lactoferrin in the auxiliary component may be configured to nasally separate from each other. In such a case, a nasal solution composed of phosphorylated oligosaccharide calcium and, if necessary, a nasal drug component is placed in one container, and a nasal solution composed of lactoferrin and, if necessary, a nasal drug component, in another container. Put in. Then, the nasal drop is performed with the nasal solution in one of the containers, and after a while, the nasal solution is performed with the nasal solution in the other container. Thereby, the nasal drop time of phosphorylated oligosaccharide calcium and lactoferrin can be shifted, and mixing of phosphorylated oligosaccharide calcium and lactoferrin in the nose can be prevented.

According to the nasal solution having the structure described above, lactoferrin passes through the blood-brain barrier from the nasal capillaries through the nasal nose, and calcium ions associated with lactoferrin are spread into the brain blood, which is unique to Alzheimer's. Alzheimer's disease can be improved by eliminating the lack of calcium ions in the brain blood. In addition, according to the present invention, the liquid oral care composition itself may be embodied as a nasal solution.

Moreover, in this invention, you may apply to the cosmetics with which the component which consists of a mixture ratio of the oral care composition mentioned above was mixed. When it is embodied as a cosmetic, it is embodied as a cosmetic containing an auxiliary component composed of the blending ratio of the above-described oral care composition and a cosmetic component contained in a normal cosmetic. These cosmetics are foundations or creams for application to the skin, and other cosmetic liquids. Cosmetic ingredients include arbutin, fullerene, tranexamic acid, hydroquinone, yokuinin extract, placenta extract and other so-called whitening ingredients, phosphorus Ascorbyl acid sodium, ascorbyl phosphate Mg, ascorbyl tetrahexyldecanoate, ascorbyl palmitate, so-called vitamin C derivatives, hyaluronic acid sodium, water-soluble collagen, placenta extract, ceramide 2, ceramide 3, ceramide 6 and other moisturizing ingredients, astaxanthin Anti-aging ingredients such as coenzyme Q10, EGF (human oligopeptide), platinum nanocolloid, retinoic acid tocopheryl, retinol, etc., but are not limited to these, and any other cosmetic ingredients may be mixed It may be a thing.

Supplied components are contained in an amount of 0.01 to 20% by mass% based on the total mass of the cosmetic. Incidentally, the phosphorylated oligosaccharide calcium and lactoferrin in the auxiliary component may be configured to be applied to the skin separately from each other. In such cases, the phosphorylated oligosaccharide calcium and, if necessary, cosmetics comprising cosmetic ingredients are placed in one container, and the lactoferrin and, if necessary, cosmetics comprising cosmetic ingredients are placed in another container. . Then, the cosmetic in one of the containers is applied to the skin, and after a while, the cosmetic in the other container can be applied to the skin for treatment. Thereby, the makeup time of phosphorylated oligosaccharide calcium and lactoferrin can be shifted, and mixing of phosphorylated oligosaccharide calcium and lactoferrin on the surface of the skin can be prevented.

According to the cosmetic composition having the above-described structure, the calcium ion of phosphorylated oligosaccharide calcium is combined with lactoferrin to cause penetration into the horny layer of the skin and acts as a calcium ion localized in the epidermal granule layer. And the localization of calcium in the epidermis can be improved. As a result, symptoms such as rough skin, dullness, and dry skin can be improved. In addition, according to the present invention, the cream-type or powder-type oral care composition itself may be embodied as a cosmetic.

Further, in the present invention, it is applied to a skin or hair cleaning composition such as a hair shampoo, body shampoo, cleansing, facial cleansing foam, etc., in which the components comprising the blending ratio of the oral care composition described above are mixed. May be. When embodied as a cleaning composition for skin or hair, skin containing an auxiliary component comprising the above-mentioned blending ratio of the oral care composition and a cleaning component contained in normal skin or hair detergent Or it is embodied as a cleaning composition for hair. This skin or hair cleaning composition is composed of, for example, powder, solid, paste, or liquid. In the following example, a case where the liquid is constituted will be described as an example. The cleaning component is mainly composed of water and a surfactant. Surfactants include higher alcohol surfactants, amino acid surfactants, betaine surfactants (amphoteric surfactants), nonionic surfactants (nonionic surfactants), and natural surfactants. Can be mentioned. In addition to this cleaning component, silicon, menthol, moisturizing components, soap, cocoon oil, and the like are also added.

The auxiliary component is contained in an amount of 0.1 to 10% by mass based on the total mass of the cleaning composition for skin or hair. By washing the hair and skin with such a skin or hair cleaning composition, the action of feeding calcium ions and lactoferrin into the inside of the hair and the epidermal layer of the skin can occur, and the quality of the hair and skin can be improved. It becomes.

Moreover, in this invention, you may apply to hair treatment materials, such as the rinse, the conditioner, the treatment, and the hair-styling (including gel, mousse, spray), etc. with which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. . When it is embodied as a hair treatment material, it is constituted by containing an auxiliary component and a hair treatment component comprising the blending ratio of the oral care composition described above. The hair treatment component is composed of, for example, powder, solid, paste, or liquid. In the following example, a case where the liquid is constituted will be described as an example. Hair treatment ingredients include rinse, conditioner, treatment, purified water, reduced water, glycerin, squalane, moisturizer, oil, aminoethylaminopropylmethicone dimethicone, higher alcohol, plant seed oil, medform Estolides, cholesterol, aloe extract, olive oil fatty acid glycerin, biohyaluronic acid and the like. The hair treatment component is composed of liquid oil, polymer, solid oil, surfactant, alcohol, moisture, propellant (gas), fragrance, preservative, stabilizer, silicon, etc. Has been.

Auxiliary components are contained in an amount of 0.1 to 10% by mass% based on the total mass of the hair treatment material. By treating the hair with such a hair treatment material, an action of fixing lactoferrin and phosphorylated oligosaccharide calcium ions to the hair root by electrolysis of the anion channel occurs, and effective hair treatment can be performed.

Moreover, in this invention, it may be applied to the food composition in which the component which consists of a compounding ratio of the above-mentioned oral care composition was mixed. When embodied as a food composition, it is embodied as a food composition containing an auxiliary component composed of the blending ratio of the oral care composition described above and an edible component constituting a normal food or confectionery. . This food composition is composed of nutrients such as proteins, lipids, carbohydrates, calcium, vitamins, and carotene. The confectionery here includes, for example, luxury items such as gum and candy.

Supplied components are contained in an amount of 0.01 to 30% by mass% based on the total mass of the food composition. In addition to normal nutrition, such a food composition enables the action of lactoferrin to transcend the blood-brain barrier into the cerebrospinal fluid and treat neurodegenerative diseases such as Alzheimer's disease. It becomes possible to prevent. In addition, phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other to secrete a large amount of saliva. As a result, drastic secretion of saliva occurs in the oral cavity, and even a person with dry mouth symptoms can make a food that is easy to eat through saliva. Furthermore, it is possible to treat the meal remaining in the oral cavity after the meal through saliva with increased secretion amount, which contributes to the health promotion in the oral cavity.

In the present invention, the composition may be applied to a beverage composition in which components having the blending ratio of the oral care composition described above are mixed. When embodied as a beverage composition, it is embodied as a beverage composition containing an auxiliary component composed of the above-mentioned blending ratio of the oral care composition and a beverage component constituting a normal beverage. This beverage composition is composed of soft drinks, carbonated drinks, alcoholic beverages, etc., and is composed of moisture, coffee, fragrance, colorant, sugar, vitamin C, salt, fruit extract, alcohols and the like. .

Auxiliary components are contained in an amount of 0.01 to 20% by mass% based on the total mass of the beverage composition. Such a beverage composition makes it possible to exert the action of translocating to the cerebrospinal fluid through the blood-brain barrier of lactoferrin in addition to normal water and nutrient intake, and neurodegenerative diseases such as Alzheimer's disease Can be treated and prevented. In addition, phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other to secrete a large amount of saliva. As a result, drastic secretion of saliva occurs in the oral cavity, which contributes to health promotion in the oral cavity.

Moreover, in this invention, you may apply to the seasoning composition with which the component which consists of a mixture ratio of the oral care composition mentioned above was mixed. When it is embodied as a seasoning composition, it is embodied as a seasoning composition containing an auxiliary component consisting of the blending ratio of the oral care composition described above and a seasoning component constituting a normal seasoning. The This seasoning composition is composed of liquid, solid, powder, etc., in addition to salt, soy sauce, sugar, vinegar, miso, chili oil, dressing, mayonnaise, ketchup, tabasco, pepper, cinnamon chili, It is represented by mirin, cooked liquor, Japanese-style seasoning (tsuyu, ponzu), but other than this, it may be composed mainly of amino acids such as umami seasoning. .

Auxiliary components are contained in an amount of 0.01 to 10% by mass% based on the total mass of the seasoning composition. With such a seasoning composition, it is possible to exert the action of lactoferrin to transcend the blood-brain barrier to cerebrospinal fluid and to treat and prevent neurodegenerative diseases such as Alzheimer's disease It becomes. In addition, phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other to secrete a large amount of saliva. As a result, drastic secretion of saliva occurs in the oral cavity, which contributes to health promotion in the oral cavity.

Furthermore, according to the present invention, lactoperoxidase may be contained in an amount of 1 to 20% by mass with respect to the total mass of auxiliary components. Like lactoferrin, this lactoperoxidase is a biological defense component contained in saliva and milk and is an enzyme that exhibits antibacterial action against various bacteria such as periodontal disease bacteria. When this lactoperoxidase is less than 1% by mass with respect to the total mass of auxiliary components, the antibacterial action cannot be expressed more effectively. On the other hand, when this lactoperoxidase is more than 20% in mass% with respect to the total mass of auxiliary components, the effect is saturated. For this reason, in order to suitably express the antibacterial action by this lactoperoxidase, it is desirable to contain 1 to 20% by mass% based on the total mass of the auxiliary components.

In addition, although this invention demonstrated taking the case where it comprised by the two-component system of a main component (a pharmaceutical ingredient, an edible ingredient, a component for drinks), and an auxiliary component in any embodiment, it is limited to this. It is not something. That is, you may make it comprise only an auxiliary component. In such a case, any chemical solution, cosmetic, food composition, beverage composition, etc. is composed of 100% of the auxiliary ingredients, and the phosphorylated oligosaccharide calcium and lactoferrin constituting the auxiliary ingredients are mixed in the above-described ratio. Will be. Further, even in the case of being constituted by a two-component system of a main component and an auxiliary component, the content ratio of the auxiliary component is not limited to the above-described range, and may be between 0.1 and 100%. You may be comprised by what content ratio.

The present invention can also be applied to a hypothermia-improving agent. This hypothermia improving agent is a hypothermia improving agent that promotes an increase in body temperature when taken, and contains an auxiliary component, and this auxiliary component is a phosphorylated oligosaccharide in mass% with respect to the total mass of the auxiliary component. It contains calcium: 1-30%, lactoferrin: 0.01-10%, magnesium sulfate: 1-70%. At this time, the auxiliary component may contain 1 to 70% by mass% of the hypothermia improver with respect to the total mass.

Next, the reason for limiting the components and content of the hypothermia improving agent to which the present invention is applied will be described. In addition, the content of each component is expressed by mass% with respect to the total mass of the auxiliary component, and when expressing the mass%, it is simply expressed as%. The reasons for the limitation of phosphorylated oligosaccharide calcium: 1-30% and lactoferrin: 0.01-10% are the same as above, so magnesium sulfate: 1-70%, total of vitamin B group: 1-10% Blood circulation promoter: The reason for the limitation of 10 to 30% will be described. The rest of the hypothermia improver is the same as described above.

Magnesium sulfate: 1-70%
Magnesium sulfate is easily soluble in water, and when it reacts with water in the esophagus, it causes an action of generating heat of about 45 ° C. Thereby, it becomes possible to raise basal metabolism by raising body temperature. As a result, in combination with the above-described lactoferrin, it exhibits a function that can synergistically promote an increase in body temperature.

Especially this magnesium sulfate ionizes magnesium when dissolved in water, and it is difficult to take it, but it can effectively absorb magnesium which is a mineral necessary for the human body. As a result, the balance between calcium and magnesium can also be optimized, so that the so-called calcium paradox, in which calcium is fixed to cells that should not accumulate calcium such as arterial cells, can be suppressed. It also has the effect of preventing high blood pressure and the like.

Furthermore, magnesium ions obtained by decomposing this magnesium sulfate are also minerals necessary for the vitamin B group described later to exert an effect of increasing body temperature in the body.

Further, magnesium ions obtained by decomposing magnesium sulfate also have a function of making lactoferrin agglomerate in order to prevent decomposition by gastric acid, like calcium ions.

When this magnesium sulfate is less than 1%, it becomes difficult to exert the above-mentioned effect of increasing the basal body temperature. On the other hand, when the magnesium sulfate exceeds 70%, the effect is saturated and the stool becomes loose. For this reason, magnesium sulfate is 1 to 70%.

Total of B vitamins: 1-10%
The vitamin B group is a concept including all substances to which vitamin B is attached, for example, vitamin B1, vitamin B2, vitamin B6, niacin, pantothenic acid, biotin, vitamin B12, folic acid and the like. B vitamins act as coenzymes for all enzymes and are called metabolic vitamins. They produce body temperature for humans to live and produce energy to move muscles. Among them, vitamin B1 plays a function of further promoting the power to generate glucose by converting glucose in the body into energy, and vitamin B2 contributes to an increase in body temperature by adding body fat to energy. By containing these vitamin B groups, it acts to increase body temperature synergistically with lactoferrin. In addition to this, this vitamin B group acts to gradually absorb lactoferrin reaching the intestine in the intestinal tract and spread it to cells in the body, so to speak, it is a substance that acts as a partner for lactoferrin. . In addition, this vitamin B group is difficult to act only by ingesting vitamin B1, vitamin B2, vitamin B6, niacin, pantothenic acid, biotin, vitamin B12, folic acid, etc. individually, and it acts as a mixture of these. Has been proven.

In addition, these vitamin B groups are undoubtedly essential nutrients for making energy for human beings to live, but it is difficult to always take them from their normal diet. For this reason, it is considered that there are a substantial number of those who are deficient in this vitamin B group. However, in the present invention, the vitamin B group is contained, so that nutrients that are often deficient are ingested evenly. There is an advantage that can be done.

When the total amount of this vitamin B group is less than 1%, the above-mentioned effect of increasing body temperature, the effect of spreading lactoferrin to cells in the body, etc. cannot be exhibited. On the other hand, if the total of the vitamin B group exceeds 10%, the effect is saturated. For this reason, the total amount of vitamin B group is 1 to 10%. In addition, in this invention, it is not essential to contain this vitamin B group.

Blood circulation promoter: 10-30%
The blood circulation promoting agent is composed of a spice that can promote blood circulation, such as a chickpea extract, ginger, pepper, pepper, and salamander, and a food and drink material. These blood circulation promoters can promote blood circulation and increase the function of raising body temperature by lactoferrin. This blood circulation promoter can distribute lactoferrin dissolved in the blood to capillaries at the end of the body. When this blood circulation promoter is less than 10%, the function of raising body temperature by such lactoferrin cannot be increased. On the other hand, if the blood circulation promoter exceeds 30%, the stimulation is excessively strong and difficult for the patient to take. Therefore, the blood circulation promoter is 10 to 30%.
The balance may contain sweeteners, acidulants, fragrances and the like. As the sweetener, acidulant, and fragrance, any known one may be applied.

Further, EPA (eicosapentaenoic acid) or nut kinase may be added to the balance. These EPA and nut kinase further improve blood circulation by further increasing blood. Moreover, EPA and nut kinase can lower the level of neutral fat in the blood and lower the level of cholesterol, and work to keep the blood healthy. Due to the above-described effects of these EPA and nut kinase, it is possible to improve poor blood circulation, which is a cause of cooling, and to improve cooling. The EPA and the nut kinase each contain 0.3 to 3%, and thereby achieve the desired effect described above.

Moreover, as shown in FIG. 1, you may comprise as the tablet 10 by which the auxiliary | assistant component 2 is coat | covered on the surface of the nucleus agent 1 containing a chemical | medical agent component. When the auxiliary component 2 is coated on the surface of the nucleating agent 1, the nucleating agent 1 may be exposed because there are portions that are not completely covered by the auxiliary component 2. That is, the auxiliary component 2 may cover at least a part of the nucleating agent 1. In addition to the form shown in FIG. 1, the auxiliary component and the drug component may be mixed with each other to constitute one tablet.

By including such a tablet in the mouth, phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other and secrete a larger amount of saliva. As a result, drastic secretion of saliva occurs in the oral cavity, and even a person with dry mouth symptoms can easily take tablets through saliva.

Further, in the present invention, the present invention may be applied to a pharmaceutical comprising a powdery drug or a granular drug mixed with the auxiliary component having the above-mentioned blending ratio. Specifically, a powdery drug containing a powdery auxiliary ingredient having the above-mentioned blending ratio and a drug ingredient including an active ingredient made of powder, or an effective substance consisting of a granular auxiliary ingredient and a granule It becomes a pharmaceutical embodied as a granular drug containing a drug component containing the ingredient. These powdered drugs or granular drugs may be encapsulated in a capsule and distributed and used. Incidentally, since this drug component is the same as the above-described tablet, the following description is omitted by citing such description.

By including such a powder or granular drug in the mouth, the phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other and secrete a larger amount of saliva. As a result, drastic secretion of saliva in the oral cavity occurs, and even a person with dry mouth symptoms can easily take a powder or granular drug through saliva.

Next, a method for producing a pharmaceutical having the above-described configuration will be described. FIG. 2 shows a flow of a pharmaceutical production method to which the present invention is applied.

First, a pharmaceutical manufacturer manufactures a nucleating agent 1 containing the above-described drug components. The nucleating agent may be configured in any form such as a tablet, a liquid, a granule, and a powder as long as it is a drug component. The nucleating agent 1 manufactured by a pharmaceutical manufacturer is normally distributed and sold in the market as it is. However, according to the present invention, such a nucleating agent 1 was obtained by a processor. Above, the operation | work which adds an auxiliary component with respect to this will be performed.

In such a case, the processor first obtains the nucleating agent 1. The nucleating agent 1 may be obtained through any method, but in any case, the nucleating agent 1 is transported from the outside or inside to the site where the processor actually performs the processing. It is essential to come.

The processor adds the auxiliary component 2 to such a nucleating agent 1. The addition of the auxiliary component 2 to the nucleating agent 1 may be performed in any form. As this addition method, the auxiliary component may be simply mixed with the nucleating agent 1 or the auxiliary component 2 may be coated on the conveyed nucleating agent 1. The coating of the auxiliary component 2 may be performed, for example, by spraying the nucleating agent 1 with a spray or by means such as coating. The processor distributes and sells the medicine composed of the tablet 10 obtained by adding the auxiliary component 2 to the nucleating agent 1 in this way.

Incidentally, the present invention is not limited to the flow shown in FIG. 2, and for example, the present invention can be applied to cases where the pharmaceutical manufacturer and the processor are the same company. In such a case, the nucleating agent 1 manufactured in the drug manufacturing department within the operator is transported to the processing department, and the auxiliary department 2 is similarly added to the nucleating agent 1 in the processing department. Even in such a case, the nucleating agent 1 conveyed in the same manner is processed. The meaning of this transport is not limited to a belt conveyor, but is simply artificially transported from another location and processed by taking out what is stored in the storage. It may be.

In addition, in the step of adding auxiliary component 2, auxiliary component 2 containing phosphorylated oligosaccharide calcium and lactoferrin may be added to nucleating agent 1 as a whole, or phosphorylated oligosaccharide calcium and lactoferrin are separately added. You may make it add to.

In addition, in the step of adding auxiliary component 2, it is desirable to add auxiliary component 2 so that it is contained in an amount of 0.01 to 50% by mass with respect to the total mass of the pharmaceutical, but the present invention is not limited to this. It may come off.

FIG. 3 shows an example in which information on the patient 6 scheduled to be taken is acquired and reflected in the design of the medicine. First, information is acquired from a patient 6 who is scheduled to take a medicine. As this information to be acquired, for example, if it is a tablet to be included in the oral cavity, information on the salivary secretion of the patient 6 may be acquired. When applied as eye drops, tears from the lacrimal gland You may make it acquire the information regarding the secretory property. Moreover, when applying as a nasal spray, you may make it acquire the information regarding the amount of runny nose.

実際 Based on the information obtained next, actually design the drug. In this design, for example, when information on the secretory property of a patient's saliva is acquired, the phosphorylated oligosaccharide calcium and lactoferrin contents are designed to vary depending on the secretory property of the saliva. For example, when saliva secretion is high, it is not necessary to promote saliva secretion so much through the auxiliary component 2, and therefore the phosphorylated oligosaccharide calcium and lactoferrin contents are set lower. On the other hand, in the case of a dry mouse state with low saliva secretion, it is highly necessary to further promote saliva secretion through the auxiliary component 2, so that the contents of phosphorylated oligosaccharide calcium and lactoferrin are further increased. Set. Information regarding the contents of the set phosphorylated oligosaccharide calcium and lactoferrin is notified in the adding step of the auxiliary component 2, and is used as the added amounts of phosphorylated oligosaccharide calcium and lactoferrin in the adding step. If the acquired information is not about saliva secretion but information about tear secretion from the lacrimal gland, it should be set to increase or decrease the amount of phosphorylated oligosaccharide calcium or lactoferrin depending on the amount of tear secretion It becomes.

In this way, by introducing a design process for the content of phosphorylated oligosaccharide calcium and lactoferrin, it is possible to provide an optimal drug according to the needs of the patient.

Incidentally, the present invention includes at least an information acquisition process for acquiring information on the patient described above and a design process for designing the contents of phosphorylated oligosaccharide calcium and lactoferrin contained in the auxiliary component to be added based on the acquired information. It may be embodied as a designed method. That is, the present invention includes a consulting business that performs the above-described information acquisition process and design process.

By the way, in the design process, for example, when a personal computer (PC) or the like is used and information about the patient is input to the PC, the optimum content is automatically output via the pre-installed design software. It may be. This design software is composed of a program for changing the contents of phosphorylated oligosaccharide calcium and lactoferrin in accordance with the input information about the patient and outputting them. For example, if the amount of saliva per minute is 30 cc or more, phosphorylated oligosaccharide calcium is 5% and lactoferrin is 2%. If the amount of saliva per minute is less than 10 cc, phosphorylated oligosaccharide calcium is 20%. %, Lactoferrin is set to 8%, and so on. Of course, the upper and lower limits of the phosphorylated oligosaccharide calcium and lactoferrin contents are programmed to be in the above-described ranges.

Further, in this design process, the auxiliary component may be designed to be contained in an amount of 0.01 to 50% by mass with respect to the total mass of the pharmaceutical, but it is not limited to this. For example, when a pharmaceutical product is composed of a single auxiliary component, the auxiliary component is 100% in terms of mass% with respect to the total mass of the pharmaceutical product, but such a range is also included in the design method to which the present invention is applied.

The present invention can be applied to a method for producing a chemical composition in addition to a method for producing a pharmaceutical product for treating a human body. In such a case, the chemical composition contains a main component that exhibits a predetermined effect and an auxiliary component added to the main component. Hereinafter, the example of the main component which comprises a chemical composition is demonstrated.

The chemical composition includes a main component and an auxiliary component. The details of the auxiliary component are as described above. The auxiliary component is contained in an amount of 0.01 to 50% by mass% based on the total mass of the chemical composition. When the auxiliary component is less than 0.01% by mass% with respect to the total mass of the chemical composition, the above-described effects as the auxiliary component cannot be exhibited. On the other hand, even if this auxiliary component is contained in an amount exceeding 50% by mass% with respect to the total mass of the chemical composition, the effect is saturated. In addition, you may make it comprise a chemical composition with an auxiliary component single-piece | unit.

Next, a method for producing a chemical composition having the above-described configuration will be described. FIG. 4 shows a flow of a method for producing a chemical composition to which the present invention is applied.

First, the manufacturer manufactures the main agent 11 containing the main components as described above. The main agent 11 may be configured in any form such as solid, liquid, granule, powder. The main agent 11 to be produced is normally distributed and sold in the market as it is. However, according to the present invention, after such a main agent 11 is obtained by a processor, Thus, an operation of adding an auxiliary component is performed.

In such a case, the processor first obtains the main agent 11. The main agent 11 may be obtained through any method, but in any case, the main agent 11 is conveyed from the outside or the inside to the site where the processor actually performs the processing. Is essential.

The processor adds the auxiliary component 12 to such a main agent 11. The auxiliary component 12 may be added to the main agent 11 in any form. As this addition method, the auxiliary component 12 may be simply mixed with the main agent 11, or the auxiliary component 12 may be coated on the main agent 11 that has been conveyed. The coating of the auxiliary component 12 may be performed, for example, by spraying the main agent 11 by spraying or by means such as coating. The processor distributes and sells the pharmaceutical comprising the chemical composition 20 obtained by adding the auxiliary component 12 to the main agent 11 in this way.

Incidentally, the flow is not limited to the flow shown in FIG. 4, and it is of course possible to apply the case where the manufacturer and the processor are the same company. In such a case, the main agent 11 manufactured in the manufacturing department in the business operator is transported to the processing department, and the auxiliary department 12 is similarly added to the main ingredient 11 in the processing department. Even in such a case, the main agent 11 conveyed in the same manner is processed. The meaning of this transport is not limited to a belt conveyor, but is simply artificially transported from another location and processed by taking out what is stored in the storage. It may be.

In addition, in the step of adding the auxiliary component 12, the auxiliary component 12 containing phosphorylated oligosaccharide calcium and lactoferrin may be added to the main agent 11 as a unit, or phosphorylated oligosaccharide calcium and lactoferrin are separately added. You may make it add.

Further, in the step of adding the auxiliary component 12, it is desirable to add the auxiliary component 12 in an amount of 0.01 to 50% by mass% based on the total mass of the chemical composition, but the present invention is not limited to this. It may be out of range.

FIG. 5 shows an example in which information on the subject 16 scheduled to be treated is acquired and reflected in the design of the chemical composition. First, information is acquired from the subject 16 who is scheduled to perform the chemical composition. The treatment here includes, for example, a case where a chemical composition embodied as a cosmetic is applied to the skin, a case where hair is washed using a chemical composition embodied as a hair cleanser, and the like. As the information to be acquired, for example, if the chemical composition is a food or drink, information on the saliva secretion of the patient 6 may be acquired. You may make it acquire the information regarding the quantity and quality of sebum.

* Based on the information obtained next, the chemical composition is actually designed. In this design, for example, when information on the salivary secretion of the subject 16 is acquired, the contents of phosphorylated oligosaccharide calcium and lactoferrin are varied according to the salivary secretion. . For example, when salivary secretion is high, the necessity of promoting saliva secretion through the auxiliary component 12 is not so high, so the contents of phosphorylated oligosaccharide calcium and lactoferrin are set lower. On the other hand, in the case of a dry mouse state with low saliva secretion, it is highly necessary to further promote saliva secretion through the auxiliary component 12, so that the contents of phosphorylated oligosaccharide calcium and lactoferrin are further increased. Set. Information regarding the contents of the set phosphorylated oligosaccharide calcium and lactoferrin is notified in the adding step of the auxiliary component 12, and is used as the added amounts of phosphorylated oligosaccharide calcium and lactoferrin in the adding step. If the acquired information is not the saliva secretion amount but the amount of sebum, for example, the setting is made so that the contents of phosphorylated oligosaccharide calcium and lactoferrin are increased or decreased according to the amount of sebum.

In this design process, the auxiliary component may be designed to be contained in an amount of 0.01 to 50% by mass with respect to the total mass of the chemical composition, but is not limited thereto. For example, when a chemical composition is composed of a single auxiliary component, the auxiliary component is 100% in terms of mass% with respect to the total mass of the chemical composition, but such a range is also included in the design method to which the present invention is applied. Of course.

Further, according to the present invention, the chemical containing the main component described above and an auxiliary component containing phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% with respect to the total mass of the auxiliary component. It may be embodied as a treatment method for treating the composition with respect to the subject. Specific examples of this treatment are the same as those described above, but are not limited to this. The concept includes any action as long as the chemical composition comprising the above-described blending components is applied to the subject. is there.

About the manufacturing method of a food / beverage composition, it becomes a thing according to the flow similar to the manufacturing method of the chemical composition shown in FIG. The food / beverage material containing the above-mentioned components for eating and drinking corresponds to the main agent 11, and after the processor obtains such a main agent 11, an operation of adding an auxiliary component thereto is performed. The details of the method for producing the food / beverage composition will be omitted from the following description by diverting the explanation of the method for producing the chemical composition shown in FIG.

Moreover, also when acquiring the information regarding the subject 16 corresponded to the consumer who actually eats and drinks a food / beverage composition, and reflects this on the design of a food / beverage composition, it is based on the procedure similar to the flow shown in FIG. Will be executed. First, information is acquired from the subject 16 as a consumer who eats and drinks a food / beverage composition. As the information to be acquired, for example, if the chemical composition is food or drink, information on the saliva secretion of the subject 16 may be acquired, or information on the palatability of food or beverages may be acquired. You may do it.

The case of actually designing the food and beverage composition based on the acquired information is the same as the case of the chemical composition shown in FIG. 4 described above, and therefore the following explanation is given by citing such explanation. Is omitted.

By the way, in the design process, for example, when a personal computer (PC) or the like is used and information about the patient is input to the PC, the optimum content is automatically output via the pre-installed design software. This may be the same as the method for designing a chemical composition described above.

FIG. 6 shows an example of the oral cavity mounting body 31 used for actual treatment. The oral cavity mounting body 31 is configured by a denture or a mouthpiece that can be mounted on the oral cavity of the subject. An insertion pocket 32 is provided on the inner side of the oral cavity wearing body 31. The charging pocket 32 is charged with auxiliary components containing phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% with respect to the total mass of the auxiliary components. The auxiliary component is configured in a liquid form, a solid form, a granular form, a powder form, or the like.

By attaching such an oral cavity wearing body 31 to the oral cavity of the subject, the auxiliary components placed in the insertion pocket 32 are dissolved and diffused naturally into the oral cavity of the subject. Incidentally, the dissolution of this auxiliary component proceeds according to the saliva of the subject or the temperature in the oral cavity.

In this way, the auxiliary component naturally diffuses in the oral cavity, thereby promoting the secretion of saliva. In particular, with such a configuration, the auxiliary component can be gradually dissolved in the oral cavity when sleeping at night, and the dry mouth state can be prevented during sleep. In addition, by attaching the oral cavity mounting body 31 to a bedridden patient, it is possible to easily realize the supplemental component and to realize oral care for 24 hours.

Hereinafter, the present invention will be specifically described with reference to test methods, examples and comparative examples used in the present invention, but the present invention is not limited to these examples. In the following examples, when only% is described, it indicates mass%.

In the present invention, as shown in Tables 1 and 2, sample tablets obtained for experimental examination were included in the mouth of five subjects A to E, and the amount of saliva secretion was measured.

Subject A is a male in his 50s, Subject B is in his 60s, Subject C is in his 40s, Subject D is in his 50s, and Subject E is in his 50s. These subjects A to E are all persons with dry mouth symptoms. In particular, subject E is a person who is undergoing treatment with an anticancer agent after surgery for tongue cancer, and is normally in a state in which little saliva is secreted.

For each of these subjects A to E, sample tablets comprising the components shown in Tables 1 and 2 above were included in the mouth for 1 minute, and saliva accumulated in the oral cavity was discharged into a measuring cup and the amount thereof was measured. Each sample tablet is composed of a 500 mg tablet, and each component shown in Table 1 is contained in% consisting of the numerical values in the table, and the remainder is composed of a starch component such as dextrin.

Comparative Example 1 is a so-called bulk sample in which a sample tablet is simply composed of dextrin. In Comparative Examples 2 to 3, the only component that promotes salivation is sodium bicarbonate, which is composed of different contents. In Comparative Examples 4 to 7, the only component that promotes salivation is phosphorylated oligosaccharide calcium, which is composed of different contents. In Comparative Examples 8 to 10, the only component that promotes salivation is lactoferrin, which is composed of different contents.

In these Comparative Examples 2 to 10, all the subjects A to E tended to increase the saliva secretion amount as the component content increased.

Invention Examples 1 to 14 all fall within the range defined in the present invention. For example, Invention Example 3 has 16% sodium bicarbonate, 10% phosphorylated oligosaccharide calcium, and 1% lactoferrin, while Comparative Example 3 has only 16% sodium bicarbonate, Comparative Example 6. Shows only 10% phosphorylated oligosaccharide calcium, and Comparative Example 10 contains only 1% lactoferrin. Since Example 3 of the present invention exceeds the total saliva secretion amount of Comparative Examples 3, 6, and 10, a synergistic effect is exhibited by mixing these components into one composition. Conceivable.

Further, Comparative Example 11 and Invention Examples 1 to 6 each had sodium bicarbonate fixed at 16% and lactoferrin fixed at 1%, and the amount of phosphorylated oligosaccharide calcium was varied, and the amount of saliva secreted respectively. It is the result of having measured. In each of Inventive Examples 1 to 6, since phosphorylated oligosaccharide calcium was included in the range of 1 to 30%, the total amount of saliva secretion for five subjects exceeded 150 ml. In Comparative Example 11, since the phosphorylated oligosaccharide calcium exceeds 30%, the amount of saliva secretion tends to be lower than those of Invention Examples 5 and 6, and when the phosphorylated oligosaccharide calcium exceeds 30%, the raw material Cost burden increases. In addition to this, since several of the subjects who took this Comparative Example 11 complained of symptoms such as looseness of the stomach, the disadvantages of adding too much phosphorylated oligosaccharide calcium have appeared. End up.

Invention Examples 9 to 13 are examples in which the composition is composed only of phosphorylated oligosaccharide calcium and lactoferrin without adding sodium bicarbonate. In the present invention examples 9 to 13 as well, since the total saliva secretion amount of Comparative Examples 4 and 8 is exceeded, a synergistic effect by mixing these components into one composition appears. It is considered a thing.

In Inventive Example 8, the contents of phosphorylated oligosaccharide calcium and lactoferrin are the same as in Inventive Example 7, but the content of sodium bicarbonate exceeds 25% by setting the content of sodium bicarbonate to 25%. It is set as follows. It has been shown that salivary secretion can be further increased by increasing the content of sodium bicarbonate. In Example 8 of the present invention, the saliva secretion amount can be increased in this way. Although no particular report was made from the subject this time, one of the subjects who took Example 8 of the present invention complained of symptoms such as slight nausea, so this sodium bicarbonate was added. Disadvantages due to being too much will appear.

Invention Example 14 is an example in which 2% of potassium carbonate was further added. It can be seen that the amount of saliva secreted can be dramatically increased by adding potassium carbonate.

Invention Example 15 is an example containing 3% magnesium carbonate in addition to the contents of phosphorylated oligosaccharide calcium and lactoferrin shown in Invention Example 11. In Example 15 of the present invention, the amount of saliva secreted is increased in the amount of magnesium carbonate added.

Inventive Example 16 is an example containing 3% of sucralose in addition to the contents of phosphorylated oligosaccharide calcium and lactoferrin shown in Inventive Example 11. In Example 16 of the present invention, the amount of saliva secreted is increased by the amount of sucralose added.

Hereinafter, specific examples of components will be described.

An eye drop solution containing an eye drop component and an auxiliary component was prepared. The auxiliary component is composed of 2.6% liquid by mass% with respect to the total mass of the eye drop solution. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of 16% phosphorylated oligosaccharide calcium, 1% lactoferrin, and the balance being moisture. In addition, as in the case of Santen Medical 10 (registered trademark) of Santen Pharmaceutical, the eye drop component is in mass% with respect to the total amount of the eye drop component, vitamin B12 (cyanocobalamin) 0.02%, neostigmine methyl sulfate 0.005%, vitamin B6 (pyridoxine hydrochloride) Salt) 0.05%, pantenol 0.05%, potassium L-aspartate 1.0%, taurine 1.0%, chlorpheniramine maleate 0.03%, epsilon-aminocaproic acid 1.0%, dipotassium glycyrrhizinate 0.1%, tetrahydrozoline hydrochloride 0.03% In addition, sodium edetate hydrate, chlorobutanol, benzalkonium chloride solution, boric acid, d-borneol, l-menthol, and pH regulator are added. The rest of the eye drop component is moisture.

When such an eye drop component was instilled into a subject with dry eye symptoms, there was a reply that dry eye symptoms had recovered from before.

In addition, as an auxiliary component, it is composed of 16% phosphorylated oligosaccharide calcium, 1% lactoferrin, and the remainder is composed of water in mass% with respect to the total mass of the auxiliary component, and the auxiliary component is 2.6% in mass% with respect to the total mass of the eye drop solution. An example of the eye drop component composed of only water was also tested by the same test subject, but there was a reply that dry eye symptoms were recovered from the same problem.

A nasal solution containing a nasal spray component and an auxiliary component was prepared. The auxiliary component is composed of 3.6% liquid by mass% with respect to the total mass of the eye drop solution. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of phosphorylated oligosaccharide calcium 6%, lactoferrin 2.5%, and the balance being moisture. The nasal spray component contains 0.5 mg of naphazoline hydrochloride, 5 mg of chlorpheniramine maleate, 3 mg of lidocaine hydrochloride, and 0.2 mg of benzethonium chloride in 1 ml as in the case of New Lulu (registered trademark) nasal spray. , Tonicity agents, parabens, and pH regulators are added.

Due to the improvement of brain function from the clinical trial that the nasal spray component was noseed to the subject, the behavior that seemed to have acted on the parasympathetic nerve was calmed down, and the dry eye was improved and the field of view was expanded. There was a reply that symptoms that seemed to be effective had recovered from before.

In addition, as auxiliary components, it is composed of 6% phosphorylated oligosaccharide calcium, 2.5% lactoferrin, and the remainder with water in mass% with respect to the total mass of auxiliary components. The same test subject was also tested in the case where the nasal spray component was composed of only water, but there was a reply that symptoms such as dry eye and widening of the visual field were recovered from the previous time.
In addition, a nasal solution containing a nasal spray component consisting of a product name (Nazar (registered trademark)) manufactured by Sato Pharmaceutical Co., Ltd. and an auxiliary component was prepared. The auxiliary component is composed of 3.6% liquid by mass% with respect to the total mass of the eye drop solution. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of phosphorylated oligosaccharide calcium 6%, lactoferrin 2.5%, and the balance being moisture. When this was dropped on the subject, there was a similar answer.

Cosmetics containing cosmetic ingredients and auxiliary ingredients were prepared. The auxiliary component is composed of 5.2% liquid by mass% with respect to the total mass of the cosmetic. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of 12% phosphorylated oligosaccharide calcium, 1% lactoferrin, and the balance being moisture. In addition, the cosmetic ingredients are the whitening ingredients (L-ascorbic acid 2-glucoside, etc.) 2.00%, the rough skin prevention ingredients (glycyrrhizic acid 2K): 0.10%, and the moisturizing ingredients (mass%) of the total cosmetic ingredients. Concentrated glycerin: 8.00%, trehalose solution: 1.00%, sodium hyaluronate: 0.05%, oily emollient component (soybean oil) 0.03%, pH adjuster: 0.03%, thickener ( Xanthan gum: 0.30%, hydroxyethylcellulose 0.30%), solubilizer (polyoxyethylene hydrogenated castor oil): 0.5%, preservative (methylparaben: 0.21%, phenoxyethanol: 0.11%), Chelating agent (EDTA-2Na): 0.10%, natural vitamin E: 0.07%, balance: purified water is added.

When such a cosmetic was applied to the subject, there was a reply that the symptoms of rough skin, dullness, and dry skin had recovered from before.

Further, as an auxiliary component, it is composed of 12% of phosphorylated oligosaccharide calcium, 1% of lactoferrin, and the remainder is composed of water in terms of mass% with respect to the total mass of the auxiliary component. In addition, although the same test subject was also tested in the case where the cosmetic component was composed only of moisture, there was a response that the symptoms of rough skin and dullness were recovered from the previous time.

In addition, in addition to the above-mentioned components, a cosmetic containing a cosmetic ingredient consisting of a brand name of Rohto Pharmaceutical Co., Ltd. (medicinal Gokujun (registered trademark)) and an auxiliary ingredient was prepared. The auxiliary component is composed of 5.2% liquid by mass% with respect to the total mass of the cosmetic. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of 12% phosphorylated oligosaccharide calcium, 1% lactoferrin, and the balance being moisture. When such a cosmetic was applied to a subject, there was a reply that symptoms of rough skin, dullness, and dry skin were recovered from before.

A tablet containing a drug component and an auxiliary component was prepared. The auxiliary component is 2.3% by mass with respect to the total mass of the tablet, and covers the surface of the drug component. This auxiliary component is mass% with respect to the total mass of the auxiliary component, 7% phosphorylated oligosaccharide calcium, 3% lactoferrin, and the remainder is composed of starch. The drug component is the mass% of the total drug component, and the components in 9 tablets are Takadiastase N1: 150 mg, Lipase AP12: 60 mg, Akamegasiwa extract: 63 mg, Licorice powder: 150 mg, Magnesium aluminate 720 mg, Synthetic hydrotalcite 300 mg, 600 mg of magnesium hydroxide, 30 mg of funnel extract, 105 mg of powdered powder, 225 mg of cinnamon powder, 60 mg of fennel powder, 30 mg of clove powder, 75 mg of ginger powder, and 9 mg of I-menthol. When such a tablet was swallowed by a test subject, not only was the gastrointestinal condition improved, but the amount of saliva secreted when included in the mouth could be increased, and it was answered that it was easier to drink there were.

Similarly, powders and granules were prepared with the same ingredients as the tablets described above and applied to the subjects, and similar responses were obtained.

A cleansing composition (shampoo) for skin or hair containing a cleaning component and an auxiliary component was prepared. The auxiliary component is 5.6% in terms of mass% with respect to the total mass of the shampoo. This auxiliary component is in mass% with respect to the total mass of the auxiliary component, and is composed of 12% phosphorylated oligosaccharide calcium, 2% lactoferrin, and the balance is moisture. Ingredients for cleaning are mass% of total cleaning ingredients, water: 53.3%, surfactant (soap): 42.0%, foam booster: 3.0%, fragrance: 0.5%, preservative: 0.5
%, PH adjusting agent: 0.5%, conditioning agent: 0.5%. When such a shampoo was used to wash the hair of the subjects, there was a reply that dandruff was improved and that the hair was shiny.

A hair treatment material (rinse) containing a hair treatment component and an auxiliary component was prepared. The auxiliary component is 7.1% by mass% with respect to the total mass of the rinse. This auxiliary component is in mass% with respect to the total mass of the auxiliary component, and is composed of 12% phosphorylated oligosaccharide calcium, 2% lactoferrin, and the balance is moisture. The hair treatment component is the mass% of the total hair treatment component, myristyl alcohol: 5.00%, dimethicone: 1.00%, ethylhexyl isononanoate: 1.00%, (stearoxymethicone / dimethicone) copolymer: 0.50%, hydrogenated olive oil: 0.50%, diisobutyl adipate: 0.25%, diisopropyl adipate: 0.25%, lavender oil: 0.03%, glycerin: 5.00%, glycine: 1.00%, dilauroyl glutamate (cholesteryl / octyldodecyl): 0.20%, stearamide ethyl diethylamine : 3.00%, cocoyl arginine ethyl PCA: 0.20%, hydrolyzed silk: 0.01%, glycolic acid: 0.63%, hydrogenated lecithin: 0.50%, ethanol: 0.01%, the balance being water. When such a rinse was used to wash the hair of the subjects, there was a reply that dandruff was improved and that the hair was shiny.

Jelly confectionery containing edible ingredients and auxiliary ingredients was prepared. The auxiliary component is 3.1% by mass% with respect to the total mass of the confectionery. This auxiliary component is mass% with respect to the total mass of the auxiliary component, 16% phosphorylated oligosaccharide calcium, 6% lactoferrin, and the balance is moisture. The edible component consists of 82.3 g of water, 2.3 g of protein, 15.3 g of sugar, 0.1 g of fiber, and 3 mg of calcium in 100 g. When such a jelly confectionery was eaten by a subject, there was a reply that a large amount of saliva was promoted.

A beverage composition containing a beverage component and an auxiliary component made of “Southern Alps Natural Water” (registered trademark) manufactured by Suntory Ltd. was prepared. The auxiliary component is 10% by mass% with respect to the total mass of the beverage composition. This auxiliary component is mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium 12%, lactoferrin 4%, and the balance is moisture. In addition, the beverage component is “Southern Alps Natural Water” (registered trademark) manufactured by Suntory Ltd., sodium: 0.4 to 1.0 mg, calcium: 0.6 to 1.5 mg, magnesium: 0.1 to 0.3 mg, potassium: 0.1 to 0.5 mg, Hardness: 30 and pH: about 7. When such a drink was allowed to be drunk by a subject, there was a reply that a large amount of saliva was promoted.

The seasoning which contains the seasoning component and auxiliary component which consist of soy sauce made from Kikkoman company was produced. The auxiliary component is 5% by mass% based on the total mass of the seasoning. This auxiliary component is mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium 12%, lactoferrin 4%, and the balance is moisture. The seasoning ingredients are soy sauce manufactured by Kikkoman Corporation. When such a seasoning was used by the test subject, there was a reply that the taste was mild.

In the present invention, as shown in Tables 3 and 4, sample tablets obtained for experimental examination were included in the mouth for five subjects A to E, and the amount of saliva secretion was measured.

For each of these subjects A to E, sample tablets comprising the components shown in Tables 3 and 4 below were included in the mouth for 1 minute, and saliva accumulated in the oral cavity was discharged into a measuring cup and the amount thereof was measured. Each sample tablet is composed of a 500 mg tablet, and each component shown in Tables 1 and 2 is contained in% consisting of the numerical values in the table, and the remainder is composed of a starch component such as dextrin.

Comparative Examples 1 to 10 in Table 3 are the same as Comparative Examples 1 to 10 in Table 1 described above. Comparative Example 11 is an example in which the content of phosphorylated oligosaccharide calcium is less than 1%, which is the lower limit, but it is shown that the secretion amount of saliva has not increased so much. Comparative Example 13 is an example in which lactoferrin is less than the lower limit of 0.01%.

Invention Examples 17-20, 28 and 29 are all examples containing phosphorylated oligosaccharide calcium: 1% to less than 4% and lactoferrin: 0.01% to 10%. In both cases, the amount of saliva secreted is larger than in Comparative Examples 2-11 and 13. Invention Example 5-9 is an example containing phosphorylated oligosaccharide calcium: 4% to 30%, lactoferrin: 0.01% to less than 0.2% or more than 3% to 10%. In both cases, the amount of saliva secreted is larger than in Comparative Examples 2-11 and 13.

On the other hand, since the content of phosphorylated oligosaccharide calcium is 12% in Comparative Example 12, it can be seen that the effect is saturated. In addition, since the content of phosphorylated oligosaccharide calcium is high, the raw material cost has increased accordingly.

Examples 24, 25 and 29 of the present invention are examples in which sodium bicarbonate is further added to phosphorylated oligosaccharide calcium and lactoferrin included in the range specified in the present invention, but the amount of saliva secreted is further increased. I understand that Inventive Example 26 is an example in which 2% of potassium carbonate was further added. It can be seen that the amount of saliva secreted can be dramatically increased by adding potassium carbonate.

サンプル Sample tablets obtained for experimental investigation of tooth pain relieving agents were put in the mouth of the subjects, and interviews were conducted to hear the effects of tooth pain relief.

Sample tablets were prepared by mixing auxiliary components shown in Table 5 below and main components. The numerical values in Table 5 are expressed in mass% with respect to the total mass.

The test subject was a male in his 50s, and in the diagnosis of a dentist, the caries reached the pulp in the lower first premolar and received a diagnosis of C3. In addition, interviews with subjects prior to the experiment confirmed that they had subjective symptoms of toothache.

The subject was asked to bite the sample tablet over 10 minutes through the lower first premolar with caries, and evaluated the pain relief effect in 5 stages. It is determined that the closer the relaxation effect in the table is to 5, the greater the relaxation effect and the more the toothache was cured. On the other hand, the closer the relaxation effect in the table is to 1, the smaller the relaxation effect, and it is judged that the toothache is hardly cured.

Each sample tablet is composed of a 500 mg tablet, and each component shown in the table is contained by% consisting of the numerical values in the table, and the remainder is composed of a starch component such as dextrin.

Comparative Example 14 was a sample tablet composed solely of phosphorylated oligosaccharide calcium, but the effect of alleviating toothache was small. Similarly, in Comparative Example 15, the sample tablet was composed only of lactoferrin, but the effect of alleviating toothache was small.

On the other hand, Examples 30 to 32 of the present invention consisted of phosphorylated oligosaccharide calcium and lactoferrin at a content ratio within the range specified in the present invention, but reported to have a greater relief effect on toothache than the subjects. It was done.

Examples 33 to 35 of the present invention consist of phosphorylated oligosaccharide calcium and lactoferrin with a content ratio within the range specified in the present invention, and lactoperoxidase with a content ratio within the range specified in the present invention. However, a greater relief of toothache was reported than the subject. However, although the comparative example 16 comprised the content of lactoperoxidase in excess of 20%, the effect was somewhat saturated.

Hereinafter, examples of hypothermia improvers to which the present invention is applied will be described. In the following examples, when only% is described, it indicates mass%.

In the present invention, a sample composed of each component shown in Tables 6 and 7 is prepared for experimental examination, and after granulating it, 5 subjects A to E are dissolved in water and swallowed. The amount of increase in body temperature (hereinafter referred to as “increased body temperature (° C.)”) was measured. In addition to lactoferrin, phosphorylated oligosaccharide calcium, and magnesium sulfate, components constituting each sample of this experiment used Hihatsu extract as a blood circulation promoter. Moreover, the content of each component constituting the vitamin B group and the total content thereof are also shown. Furthermore, an example including EPA and nut kinase is also shown. The numerical values of the components in the table are all mass% with respect to the total mass of the auxiliary components. The body temperature before taking the sample was first measured, and then the body temperature was measured 60 to 90 minutes after taking the sample. And the difference value of the body temperature measured before and after ingesting this sample is made into the raise body temperature (degreeC).

Subject A is a man in their 40s, Subject B is in their 60s, Subject C is in their 40s, Subject D is in their 40s, and Subject E is in their 50s. All these subjects A to E complain of coldness.

For each of these subjects A to E, the hypothermia improvers (Invention Examples 36 to 54, Comparative Examples 17 to 29) containing auxiliary components consisting of the components shown in Tables 6 and 7 above are granulated. . The balance of the auxiliary component is composed of zinc-containing yeast, a bulking agent, a sour agent, a sweetener and the like. The auxiliary component contained in the hypothermia improver is 38.48% by mass% with respect to the total weight of the hypothermia improver. The remainder excluding the auxiliary component in the hypothermia agent is composed of a bulking agent composed of a starch component such as dextrin.

Since Examples 36 to 54 of the present invention are all included in the range of the components of the present invention described above, it was confirmed that the elevated body temperature was high. In particular, Examples 41 to 43 of the present invention had a higher elevated body temperature because the vitamin B group was within the above-described range. Inventive Examples 40 and 44 are examples in which the vitamin B group is added but deviate from the above-mentioned range, although this is lower in temperature rise than Inventive Examples 41 to 43, A higher temperature rise was obtained compared to the comparative example. In addition, since Inventive Example 50 further contained a chickpea extract in addition to the vitamin B group, the elevated body temperature was higher than that of Inventive Examples 41 to 43.

Inventive Examples 45 to 49 were examples in which the extract of Hibatsu was added in addition to lactoferrin, phosphorylated oligosaccharide calcium, and magnesium sulfate. In particular, Examples 46 to 48 of the present invention were included in the range of 10 to 30% defined in the present invention, and thus a particularly large increase in body temperature could be confirmed. Invention Example 49 was able to confirm a large increase in body temperature, but the panelists felt that stimulation was strong.

Inventive Example 51 is an example in which a rabbit extract is added to lactoferrin and phosphorylated oligosaccharide calcium, and Inventive Example 52 relates to vitamin B group to lactoferrin and phosphorylated oligosaccharide calcium. Although it was the example which added, all were able to confirm the expected body temperature rise.

Comparative Examples 17 and 18 are so-called bulk samples in which the auxiliary component is composed only of phosphorylated oligosaccharide calcium. Similarly, Comparative Examples 19 and 20 are samples in which the auxiliary component is composed of lactoferrin. None of these Comparative Examples 17 to 20 caused an increase in body temperature. The reason is that Comparative Examples 17 and 18 contain only phosphorylated oligosaccharide calcium in the first place, and therefore do not contain any substances that contribute to an increase in body temperature. In Comparative Examples 19 and 20, only lactoferrin that contributes to an increase in body temperature cannot be decomposed by gastric acid and reach the intestine as described above, and the desired effect of increasing the body temperature cannot be expressed.

In Comparative Examples 21 to 23, although phosphorylated oligosaccharide calcium and lactoferrin are within the range defined in the present invention, magnesium sulfate is not contained. For this reason, it is considered that magnesium ions obtained by decomposing magnesium sulfate cannot obtain the effect of increasing body temperature in the body, and it is not possible to perform the action of lumping to prevent lactoferrin from being decomposed by gastric acid. It is done.

Comparative Example 24 contains phosphorylated oligosaccharide calcium and magnesium sulfate within the range defined in the present invention, but does not contain lactoferrin.

In Comparative Example 25, although the phosphorylated oligosaccharide calcium and magnesium sulfate are within the ranges defined in the present invention, the content of lactoferrin exceeds the upper limit. For this reason, although the increase effect of body temperature can be confirmed, the increase temperature is not high compared with the example of this invention.

In Comparative Example 26, although lactoferrin and magnesium sulfate are within the range specified in the present invention, the content of phosphorylated oligosaccharide calcium is below the lower limit. For this reason, although the increase effect of body temperature can be confirmed, the increase temperature is not high compared with the example of this invention.

In Comparative Example 27, lactoferrin and magnesium sulfate are within the range defined in the present invention, but the content of phosphorylated oligosaccharide calcium exceeds the upper limit. For this reason, although the increase effect of body temperature can be confirmed, the increase temperature is not high compared with the example of this invention.

In Comparative Example 28, lactoferrin and phosphorylated oligosaccharide calcium are within the range defined in the present invention, but the content of magnesium sulfate is below the lower limit. For this reason, although the increase effect of body temperature can be confirmed, the increase temperature is not high compared with the example of this invention.

In Comparative Example 29, although the content of lactoferrin and phosphorylated oligosaccharide calcium is within the range defined in the present invention, the content of magnesium sulfate exceeds the upper limit. For this reason, there were two panelists who complained of abdominal pain associated with excessive addition of magnesium sulfate and symptoms of stool relief, although the effect of increasing body temperature could be confirmed.

In addition, when panelists A and B were asked about the impression that each of Comparative Example 22 and Invention Example 37 was ingested, it was stated that Invention Example 37 had a sense that body temperature rose earlier. The effect of increasing the body temperature of the intaker earlier based on magnesium sulfate and then increasing the body temperature of the intaker later based on lactoferrin has been revealed.

In addition, when panelists A and B were asked about the impression of taking Comparative Example 22 and Invention Example 37, it was stated that there was a sense that the body temperature was high over a long period of time. The temperature of the intake is increased earlier, based on lactoferrin, and then the intake temperature is increased more slowly, and then the temperature is increased based on the vitamin B group. The rising effect could be confirmed.

DESCRIPTION OF SYMBOLS 1

Nucleating agent

2, 12 Auxiliary component 6 Patient 10 Tablet 11 Main ingredient 20 Chemical composition 12 Auxiliary component 16 Subject 31 Oral wear body 32 Loading pocket

Claims

In an oral care composition that promotes oral health by including in the oral cavity,
In mass% with respect to the total mass of the composition,
Phosphorylated oligosaccharide calcium: 1% to less than 30%,
Oral care composition characterized by containing lactoferrin: 0.01% to 10%.
The oral care composition according to claim 1, further comprising sodium bicarbonate: 1% to 20%.
The oral care composition according to claim 1 or 2, further comprising potassium carbonate or potassium hydrogen carbonate: 1% to 5%.
The oral care composition according to claim 1, further comprising magnesium carbonate: 1 to 5%.
The oral care composition according to claim 1, further comprising sucralose: 1 to 5%.
Contains eye drop ingredients and auxiliary ingredients,
The ophthalmic solution is characterized in that the auxiliary component contains, in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10%.
Containing a nasal drug component and an auxiliary component,
The nasal solution according to any one of the above, wherein the auxiliary component contains, in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.01 to 10%
Contains cosmetic ingredients and auxiliary ingredients,
Cosmetics characterized in that the auxiliary ingredient contains phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% relative to the total mass of the auxiliary ingredient.
Contains cleaning ingredients and auxiliary ingredients,
The above-mentioned auxiliary component is a mass% with respect to the total mass of the auxiliary component, and contains phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.01 to 10%. .
Contains hair treatment ingredients and auxiliary ingredients,
The hair treatment composition according to claim 1, wherein the auxiliary component contains phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% based on the total mass of the auxiliary component.
Contains edible ingredients and auxiliary ingredients,
The food composition according to claim 1, wherein the auxiliary ingredient contains phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% relative to the total mass of the auxiliary ingredient.
Contains beverage ingredients and auxiliary ingredients,
The beverage composition according to claim 1, wherein the supplemental component contains phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% based on the total mass of the supplemental component.
Contains seasoning ingredients and auxiliary ingredients,
The above-mentioned auxiliary component contains a phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% based on the total mass of the auxiliary component.
In a method for producing a pharmaceutical product containing a pharmaceutical ingredient,
A transporting step in which a nucleating agent containing the drug component is transported;
An addition step of adding an auxiliary component to the nucleating agent that has been transported in the transport step,
In the above addition step, a method for producing a pharmaceutical product, comprising adding phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% relative to the total mass of the auxiliary ingredients.
In a method for designing a pharmaceutical product containing a pharmaceutical ingredient,
An information acquisition process for acquiring information about the patient;
Based on the information acquired in the information acquisition step, the design step of designing the phosphorylated oligosaccharide calcium and lactoferrin content contained in the auxiliary component to be added,
A method for designing a pharmaceutical, characterized in that, in the above design process, the phosphorous oligosaccharide calcium is contained in an amount of 1% to 30% and lactoferrin: 0.01 to 10% in terms of mass% with respect to the total mass of auxiliary components.
In the method for producing a chemical composition containing a main component that exhibits a predetermined effect,
A conveying step in which the main ingredient containing the main component is conveyed;
An addition step of adding an auxiliary component to the main agent that has been conveyed in the conveyance step,
In the adding step, phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% are added in mass% with respect to the total mass of the auxiliary ingredients.
In a method for designing a chemical composition containing a main component that exhibits a predetermined effect,
An information acquisition process for acquiring information about the recipient;
Based on the information acquired in the information acquisition step, the design step of designing the phosphorylated oligosaccharide calcium and lactoferrin content contained in the auxiliary component to be added,
In the above design process, the chemical composition is designed to be contained in phosphorous oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% with respect to the total mass of the auxiliary components. Method.
In the method for producing a food / beverage composition containing a food / beverage component,
A conveying step in which a food or drink containing ingredients for eating or drinking is conveyed;
An addition step of adding an auxiliary component to the food and drink that has been transported in the transport step,
In the said addition process, phosphorylated oligosaccharide calcium: 1-30% and lactoferrin: 0.01-10% are added with the mass% with respect to the auxiliary | assistant component total mass, The manufacturing method of the food / beverage composition characterized by the above-mentioned.
In the method for designing a food / beverage composition containing a food / beverage component,
An information acquisition process for acquiring information about the restaurant;
Based on the information acquired in the information acquisition step, the design step of designing the phosphorylated oligosaccharide calcium and lactoferrin content contained in the auxiliary component to be added,
In the above-mentioned design process, the food / beverage composition characterized by being designed to be contained in phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% with respect to the total mass of auxiliary ingredients Design method.
A chemical composition containing a main component exhibiting a predetermined effect and an auxiliary component containing phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% by mass% with respect to the total mass of the auxiliary component A treatment method characterized by performing treatment on a practitioner.
Wearing an oral wear body containing an auxiliary ingredient containing phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% in the mass% of the auxiliary ingredient in the subject's oral cavity A method of treatment characterized by gradually dissolving the auxiliary components inserted into the oral cavity implant in the oral cavity of the subject.
Auxiliary ingredients containing phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% in mass% with respect to the total mass of the auxiliary ingredients are inserted into the oral cavity of the subject, An oral wearing body characterized by gradually dissolving the auxiliary component in the oral cavity of a subject.
Contains auxiliary ingredients,
The auxiliary component is characterized by containing, in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.01 to 10%, and lactoperoxidase: 1 to 20%. Tooth pain relieving agent.
Contains auxiliary ingredients,
The auxiliary component is mass% with respect to the total mass of the auxiliary component, and contains phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.01 to 10%, magnesium sulfate: 1 to 70%. Hypothermia improver.
Contains auxiliary ingredients,
The auxiliary component is contained in mass% with respect to the total mass of the auxiliary component, and contains phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.01 to 10%, and total of vitamin B group: 1 to 10%. Characteristic hypothermia improver.
Contains auxiliary ingredients,
The auxiliary component is characterized by containing, in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10%, and blood circulation promoter: 10-30%. Hypothermia improver.